Detection of mutations in the cDNA of the proliferation marker Ki-67 protein in four tumor cell lines

Cancer Genetics and Cytogenetics

Volumn 149, Issue 1, 2004, Pages 81-84

  Bubán, Tamás ^a,b   Schmidt, Mirko ^a   Broll, Rainer ^a   Antal Szalmás, Péter ^b   Duchrow, Michael ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; KI 67 ANTIGEN;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ESCHERICHIA COLI; FLUORESCENCE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENE VECTOR; HUMAN; HUMAN CELL; LUNG CANCER; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; UTERINE CERVIX CANCER;

ESCHERICHIA COLI;

EID: 0842281260     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(03)00297-8     Document Type: Article

References (22)

1. Braun N., Papadopoulos T., Müller-Hermelink H.K. Cell cycle dependent distribution of the proliferation associated Ki-67 antigen in human embryonic lung cells. Virchows Arch B Cell Pathol Incl Mol Pathol. 56:1988;25-33.
2. Bruno S., Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif. 25:1992;31-40.
3. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1984;1710-1715.
4. Schrape S., Jones D.B., Wright D.H. A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. Br J Cancer. 55:1987;283-286.
5. Tazzari P.L., Bontadini A., Gobbi M., Tassi C., Dinota A., Visani G., Michieli M.G., Pileri S., Baccarani M., Tura S. Comparison of the DNA content, bromodeoxyuridine incorporation and Ki-67 antigen expression in human acute myeloid leukemia. Leuk Lymphoma. 3:1990;45-51.
6. Gerdes J., Stein H., Pileri S., Rivano M.T., Gobbi M., Ralfkiaer E., Nielsen K.M., Pallesen G., Bartels H., Palestro G., Delsol G. Prognostic relevance of tumor-cell growth fraction in malignant non-Hodgkin's lymphomas. [Letter]. [Erratum: Lancet 1987;2(8561):756.] Lancet. 2:(8556):1987;448-449.
7. Hall P.A., Richards M.A., Gregory W.M., d'Ardenne A.J., Lister T.A., Stansfeld A.G. The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J Pathol. 154:1988;223-235.
8. Holte H., De Lange Davis C., Beiske K., Stokke T., Marton P.F., Smeland E.B., Hoie J., Kvaloy S. Ki-67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumor progression in low-grade B-cell lymphoma. Int J Cancer. 44:1989;975-980.
9. Tungekar M.F., Gatter K.C., Dunnill M.S., Mason D.J. Ki-67 immunostaining and survival in operable lung cancer. Histopathology. 19:1991;545-550.
10. Fontana D., Bellina M., Gubetta L., Fasolis G., Rolle L., Scoffone C., Porpiglia F., Colombo M., Tarabuzzi R., Leonardo E. Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J Urol. 148:1992;1149-1151.
11. Locker A.P., Birrell K., Bell J.A., Nicholson I., Elston C.W., Blamey R.W., Ellis I.O. Ki-67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol. 18:1992;224-229.
12. Duchrow M., Schlüter C., Key G., Kubbutat M.H.G., Wohlenberg C., Flad H.D., Gerdes J. Cell proliferation-associated nuclear antigen defined by antibody Ki-67: a new kind of cell cycle-maintaining proteins. Arch Immunol Ther Exp (Warsz). 43:1995;117-121.
13. Schlüter C., Duchrow M., Wohlenberg C., Becker M.H.G., Key G., Flad H.D., Gerdes J. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 123:1993;513-522.
14. MacCallum D.E., Hall P.A. The biochemical characterization of the DNA binding activity of pKi-67. J Pathol. 191:2000;286-298.
15. Scholzen T., Endl E., Wohlenberg C., Sar S., Cowell I.G., Gerdes J., Singh P.B. The KI-67 protein interacts with members of the heterochromatin protein I (HPI) family: a potential role in the regulation of higher-order chromatin structure. J Pathol. 196:2002;135-144.
16. Schmidt M.H.H., Broll R., Bruch H.P., Bögler O., Duchrow M. The proliferation marker pKi-67 organizes the nucleolus during the cell cycle depending on Ran and Cyclin B. J Pathol. 199:2003;18-27.
17. Arnhold I.J., Nery M., Brown M.R., Voss T.C., VanderHeyden T.C., Adess M.E., Hurley D.L., Wajchenberg B.L., Parks J.S. Clinical and molecular characterization of a Brazilian patient with Pit-1 deficiency. J Pediatr Endocrinol Metab. 11:1998;623-630.
18. Reifenberger J., Janssen G., Weber R.G., Bostrom J., Engelbrecht V., Lichter P., Borchard F., Gobel U., Lenard H.G., Reifenberger G. Primitive neuroectodermal tumors of the cerebral hemispheres in two siblings with TP53 germline mutation. J Neuropathol Exp Neurol. 57:1998;179-187.
19. Auer H., Warncke K., Nowak D., Koops F., Jaeger U., Kurzbauer R., Ruediger H.W. Variations of p53 in cultured fibroblasts of patients with lung cancer who have a presumed genetic predisposition. Am J Clin Oncol. 22:1999;278-282.
20. Christoffers M.J., Berg M.L., Messersmith C.G. An isoleucine to leucine mutation in acetyl-CoA carboxylase confers herbicide resistance in wild oat. Genome. 45:2002;1049-1056.
21. Tu S.S., Wu W.J., Yang W., Nolbant P., Hahn K., Cerione R.A. Antiapoptotic Cdc42 mutants are potent activators of cellular transformation. Biochemistry. 41:2002;12350-12358.
22. Li R.P., Duterque-Coquillaud M., Lagrou C., Debuire B., Graf T., Stehelin D., Leprince D. A single amino-acid substitution in the DNA-binding domain of the myb oncogene confers a thermolabile phenotype to E26-transformed myeloid cells. Oncogene Res. 5:1989;137-141.